Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients diagnosed with pancreatic cancer, according to a study published in the July 1 ...

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely ...

US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The Phase Ib study (NCT06673017) is investigating PTM-101 ...

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

Among a cohort of 1,135 women ages 40 and younger with stage I through III breast cancer, the incidence of LRR was 5.6%, with ...

Patients need to rely on chemotherapy as a standard-of-care, which is started ahead of surgical interventions as a so-called "neoadjuvant chemotherapy" (NACT) in the hope to shrink or control tumors.